AUSTIN, Texas–(BUSINESS WIRE)–Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and genetic testing, today announced that it has surpassed a key milestone with over 100 peer-reviewed publications on its personalized and tumor-informed molecular residual disease (MRD) test, Signatera. Multiple validation studies on Signatera have been published in top-tier journals like Nature, Nature Medicine, Nature Cancer, Journal of Clinical Oncology, Annals of Oncology, and JAMA Oncology. Thes